Kornimate/medical-research-clean huggingface dataset:
cranberry for the prevention of urinary tract infections

Conditions: Diabetes; Urinary Infection

Summary: this research aims to evaluate the potential benefit of an oral nutritional supplement based on anthocran phytosome compared to placebo on the prevention of urinary infections, including microbiota analyzes, in postmenopausal women (\> 70 years) with diabetes. for each subject enrolled, all parameters relating to urinary infections will be assessed at the beginning (baseline), every 2 months from the start of treatment and at the end of treatment (6 months), with urine analysis and quality of life questionnaires.


Eligibility criteria:
inclusion criteria: * postmenopausal women (\> 70 years) with diabetes. * treatment with sglt-2 inhibitors * disease duration for at least 10 years, with at least 1 episode of infection the previous year and charlson's co-morbidity index\> 6.
glucose consumption during deep brain stimulation with functional [18f]fdg-brain-pet in obsessive-compulsive disorder

Conditions: Obsessive-Compulsive Disorder; Psychiatric Disorder

Summary: the purpose of this randomized, sham-controlled study is to evaluate the effectiveness of dbs therapy in individuals suffering from severe ocd and to investigate dbs treatment with functional \[18f\]fdg-brain-pet.

the overall planned study duration per subject is 36 weeks, whereby inclusion is timepoint zero and implantation of dbs will be conducted during the first four study weeks. patients will then undergo an 8-week open-label active dbs treatment phase followed by a 12-week double blind active or sham treatment and finally a 12-week crossover period with the inverse (active/sham) treatment with at least biweekly study visits. patients as well as patient handling study psychiatrists will be blinded to active/sham. in case of unbearable aggravation of the symptoms during sham, the sham-period will be shortened to a tolerable length. after maximal 38 weeks all study procedures will be completed, and active dbs treatment will be maintained as long as clinically necessary.

Eligibility criteria:
inclusion criteria: * a score of 25 or higher on the yale-brown obsessive compulsive scale * previous failure to respond to at least two medication trials with serotonin reuptake inhibitors at or, if tolerated, beyond the fda maximum recommended dose for a minimum duration over at least ten weeks each. * at least one trial with tricyclic medication at or, if tolerated, beyond the fda maximum recommended dose for a minimum duration over at least ten weeks each. * at least one trial of augmentation with antipsychotic medication, lithium, a benzodiazepine or buspirone * at least on trial of psychotherapy (cognitive behavioral therapy or comparable techniques) for at least 20 sessions * ability to provide written informed consent exclusion criteria: * any history of current or past psychotic disorder * a manic episode within the preceding three years * any current clinically significant medical or neurological disorder, that is a contraindication against dbs * any disease that could lead to an altered glucose reactivity (e.g. diabetes) * any clinically significant preoperative mri abnormality or inability to undergo presurgical mri * current or unstable remitted substance abuse or dependence except nicotine * pregnancy or high risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception * any current severe personality disorder except comorbid anankastic personality disorder * inability to follow the study protocol or adhere to operational requirements * current and unstable suicidality

Keywords: fdg-pet deep brain stimulation brain glucose consumption
artificial intelligence-supported mobile application for diabetes self-management

Conditions: Diabetes Mellitus; Artificial Intelligence (AI); Self-management

Summary: patients in the ai-supported mobile application group will be able to log in with a username and password that will be defined specifically for them. patients will be informed about how the application is used during their first interview. they will enter their personal and disease characteristics (age, gender, height, weight, hba1c, hdl, ldl) into the application at the entrance. other sections of the application will include exercise, nutrition, medication tracking, complication tracking and diabetic foot care sections. the person will be asked to enter relevant information in these fields according to their own life and condition (for example; how many times do you use insulin per day, what are your medication times, how do you spend your day in terms of exercise, how many meals do you eat, what is your diet, do you urinate frequently, are you extremely thirsty, are you hungry often, do you have numbness in your hands and feet, etc.). after the patient enters the necessary information, they will also be asked to enter their daily blood sugar measurement values into the system. thus, the individual\&#39;s hypo/hyperglycemia risk, risk analysis, nutrition recommendations, medication reminder system, exercise reminder and incentive warnings will be communicated to the individual thanks to the ai-based mobile application. the aim of this application is to reduce the risk of complications and improve the individual\&#39;s quality of life by providing personalized recommendations for all the needs of the individual, including alarms and reminders, and to support patients to continue their diabetes education and disease management more actively.

pre-test post-test control group design

Eligibility criteria:
inclusion criteria: * having been diagnosed with diabetes for at least 1 year * being between the ages of 18-65 * being open to verbal communication * being able to read and write and speak turkish * having a smart android phone and being able to use mobile applications * being willing to participate in the study exclusion criteria: * having a perception disorder and psychiatric disorder that prevents the patient from communicating, * having a condition that prevents them from using a smart phone (advanced retinopathy and neuropathy, internet problems) * being on intensive insulin treatment * having a condition that prevents them from continuing the application phase of the study * wanting to leave the study

Keywords: diabetes mellitus artificial intelligence self-management level of knowledge compliance with treatment
drug-eluting balloon vs. conventional balloon in the treatment of (re)stenosis - a randomized prospective study

Conditions: Peripheral Artery Occlusive Disease; Peripheral Artery Restenosis; Peripheral Artery Stenosis

Summary: the purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in bypass vein grafts.

drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. stenosis and restenosis is a known problem in bypass vein grafts, and drug-eluting devices might be beneficial in this field as well. in the procedure a conventional balloon is passed through the stenosis which is then dilated. after this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon. the stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. follow-up will end at 12 months.

Eligibility criteria:
inclusion criteria: * any venous bypass with stenosis warranting intervention exclusion criteria: * previous pta with drug-eluting balloon, thrombolysis, coagulopathy

Keywords: restenosis drug-eluting balloon vein graft
dapagliflozin in patients with critical illness

Conditions: Critical Illness; Sepsis

Summary: to assess the effects of dapagliflozin on a composite hierarchical endpoint in critically ill patients.

critically ill patients in the intensive care unit (icu) experience a high mortality rate. recent data indicates that the mortality rate for unplanned icu admissions exceeds 30%, highlighting the urgent need for therapies that can reduce mortality in these critical patients. defender is an investigator-initiated, multi-center, randomized, open-label clinical trial, conducted in brazilian icus. the study population will consist of participants who have been admitted to an icu with an expected length of stay of more than 48 hours with evidence of at least an acute organ dysfunction, such as hypotension, signs of acute kidney injury, and/or the need for new use of high-flow nasal catheter, noninvasive or invasive ventilation. eligible patients will be enrolled within 24 hours after the onset of organ dysfunction. participants will be randomly assigned in a 1:1 ratio to receive either dapagliflozin 10mg (for 14 days or until icu discharge, whichever occurs sooner) in addition to standard of care, or standard care alone. the primary outcome of the study is a hierarchical composite endpoint, including: i) hospital mortality, ii) initiation of kidney-replacement therapy, and iii) icu length of stay. these outcomes will be assessed up to 28 days after randomization, with censoring at the time of hospital discharge. to ensure participant safety, an independent data and safety monitoring board will periodically review the data.

Eligibility criteria:
inclusion criteria: 1. patients admitted to an intensive care unit with expected duration of admission of at least 48 hours in the opinion of the attending physician and 2. patients with at least one new organ dysfunction: 1. hypotension (mean arteria pressure below 65 mmhg or systolic blood pressure below 90 mmhg or use of vasopressors - norepinephrine, epinephrine, adrenaline, or vasopressin at any dose); 2. signs of acute kidney injury (increase in serum creatinine above 0.3 mg/dl over previous measurement or decrease in urinary output - below 0.5 ml/kg/h - in the past six hours; 3. need for new use of high-flow nasal catheter or noninvasive ventilation or invasive ventilation. exclusion criteria: 1. pregnancy or age below 18 years; 2. patient or legal representative refusal; 3. patients with chronic kidney disease on dialysis; 4. planned intensive care unit admission after elective surgery; 5. known allergy to dapagliflozin; 6. previous use of dapagliflozin or other sodium-glucose transport protein 2 inhibitor; 7. patients that cannot receive medications through oral or enteral route; 8. patients with inclusion criteria number 2 for more than 24 hours. 9. patients with type 1 diabetes or previous ketoacidosis

Keywords: dapagliflozin critical illness
validation of bladder health instrument for evaluation in women

Conditions: Lower Urinary Tract Symptoms

Summary: the prevention of lower urinary symptoms (plus) research consortium is working to optimize prevention of lower urinary tract symptoms (luts) in women and adolescent females across their life spans. the ability to measure bladder health and key risk and protective factors is crucial to the plus mission. to describe and measure the spectrum of bladder health in diverse populations, researchers need a valid and reliable instrument. to date, the consortium's work on design of a bladder health instrument has been a culmination of expert opinion, information from focus groups, and incorporation of previously validated items and language where appropriate, along with cognitive interviews of participants from the general public. the next step in the consortium's work is to prospectively collect data to test and validate bladder health instrument (bhi) items for inclusion in a final bladder health scale (bhs) that can assess the full range of bladder health of women. this will be through a combination of general population recruitment for completing mailed surveys, clinical population recruitment for completing surveys and an in-person evaluation, and postpartum women.


Eligibility criteria:
inclusion criteria: * community dwelling * age ≥18 years old * female sex assigned at birth * fluent in written and spoken english * able to read and provide informed consent exclusion criteria: * institutional living arrangement, e.g., skilled nursing, long term care or rehabilitation center * physical or mental condition that would prohibit self-administration of questionnaire either electronically or using paper and pencil (e.g., dementia/cognitive impairment/blindness/severe arthritis).

Keywords: bladder health luts plus view
inflammation, autonomic dysfunction and airway disease

Conditions: Lung Diseases; Asthma; Bronchitis; Inflammation

Summary: to determine whether airway inflammation secondary to inhalation of specific allergens and other environmental agents and functional imbalance of the autonomic nervous system played important roles in asthma and chronic bronchitis.

background: asthma and chronic bronchitis are among the most common chronic diseases afflicting middle-aged and elderly adults in the united states, respectively occurring in 4 percent and 5 percent of the population in these age groups. while chronic bronchitis is often caused by cigarette smoking and asthma often occurs in nonsmokers in association with atopy, the two conditions may be difficult to differentiate in many middle-aged and older adults and may share a number of pathophysiologic features including increased airway smooth muscle tone, increased airway responsiveness to bronchoconstricting stimuli, and bronchial mucus hypersecretion. the precise mechanisms which produce the alterations of airway function are not clear. such functional alterations may be caused by airway inflammation and abnormalities of the autonomic nervous system; however, there are little population data available regarding the importance of airway inflammation and disordered neural regulation in the pathogenesis of airway hyperresponsiveness and mucus hypersecretion. also, little is known about potential interactions between airway inflammation and disordered neural regulation of airway function in the pathogenesis of chronic airways disease. information on the relationships may offer insights into the pathophysiologic mechanisms underlying asthma and chronic bronchitis in adults. design narrative: the study was cross-sectional and used a subgroup of the normative aging study, a longitudinal study of aging in men established by the veterans administration in 1963. the study used data normally collected during nas examinations and included smoking history, socio-economic status, anthropometry, respiratory symptoms and illnesses, and pulmonary function. new data were collected on: indices of inflammation as indicated by histamine, leukotriene, and serotonin in urine; autonomic activity as indicated by urinary catecholamine excretion and heart rate variation induced by deep breathing; autonomic responsiveness as measured by pupillary alpha-adrenergic and cholinergic responses. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
an observational study on the safety and effectiveness of rituximab in patients with severe active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this prospective observational study aims to evaluate safety, application and onset of effect of rituximab in clinical routine treatment of severe active rheumatoid arthritis during the first 6 months (in case of re-therapy: 12 months).


Eligibility criteria:
inclusion criteria: * no pretreatment with rituximab * age 18 years or older * patients with active, severe rheumatoid arthritis with prescription of rituximab according to german summary of product characteristics (smpc - "fachinformation") * patients with signed informed consent * female patients with secure contraception exclusion criteria: * violation of selection criteria: 1. active severe infection 2. severe heart failure (nyha class iv) or severe, uncontrollable heart disease 3. participation in an interventional study within the last 3 months before therapy start with rituximab 4. pretreatment with rituximab 5. age \<18 years 6. known intolerability of monoclonal antibodies or chimeric monoclonal antibodies 7. known pregnancy or breastfeeding * data of patients without approval of data by the physician * patients without informed consent * double documentation
risk adapted therapy in diffuse large b cell lymphoma

Conditions: Large B Cell Lymphoma

Summary: this randomized phase ii trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large b-cell lymphoma.

objectives: 1. to compare the response rates and toxicity of r-chop versus da-epoch-r in untreated cd20+ diffuse large b-cell lymphomas. 2. to compare the event-free survival of r-chop versus da-epoch-r chemotherapy in untreated cd20+ diffuse large b-cell lymphomas. 3. to develop predictors of outcome of r-chop and da-epoch-r chemotherapy.

Eligibility criteria:
inclusion criteria: * 1. histologically documented de novo cd20+ dlbcl with stage ii, iii or iv disease. stage i primary mediastinal (thymic) dlbcl is also eligible. diagnosis should be based on an adequate tissue sample, including open biopsy or core needle biopsy. needle aspiration for primary diagnosis is unacceptable. patients must have one of the following who classification subtypes: diffuse large b-cell lymphoma (includes morphological variants: centroblastic, immunoblastic, t-cell/histiocyte rich, and anaplastic) mediastinal (thymic) large b-cell lymphoma intravascular large b-cell lymphoma patients without adequate frozen material should have a biopsy performed to obtain material. 2. patients may be entered if they have received prior limited field radiation therapy or a short course of glucocorticoids (\< 10 days) for an urgent local disease complication at diagnosis (e.g., cord compression, svc syndrome). 3. age \>16 years old. 4. ecog performance status 0-2 5. if there is suspicion of cardiac disease, a cardiac ejection fraction must show lvef \> 45%. 6. required initial laboratory values (unless non-hodgkin lymphoma): * anc ≥ 1000/μl * platelets ≥ 100,000/μl * creatinine≤ 1.5 mg/dl or creatinine clearance ≥ 50 cc/min * total bilirubin ≤ 2 mg/dl (unless a history of gilbert's disease) exclusion criteria: * 1- patients with an underlying low-grade lymphoma, such as a transformed lymphoma or low-grade lymphoma in the bone marrow, are not eligible. 2- patients with low international prognostic index are not eligible. 3- prior cytotoxic chemotherapy or rituximab. patients who have received chemotherapy for prior malignancies are not eligible. 4- active ischemic heart disease or congestive heart failure. 5- known lymphomatous involvement of the cns. a lumbar puncture prior to study is not required in the absence of neurological symptoms. 6- known hiv disease. patients with a history of intravenous drug abuse or any other behavior associated with an increased risk of hiv infection should be tested for exposure to the hiv virus. patients who test positive or who are known to be infected are not eligible. 7- pregnant and non-nursing. treatment would expose an unborn child to significant risks. women and men of reproductive potential should agree to use an effective form of contraception. 8- patients with active medical processes (e.g., uncontrolled bacterial or viral infection, bleeding) not related to their lymphoma should be excluded.
post-operative pain after uniportal vats lobectomy: does a smaller incision result in better recovery?

Conditions: Pain

Summary: post-operative pain after uniportal vats lobectomy: does a smaller incision result in better recovery? postoperative pain control remains one of the most common problems after major lung resection. pain is considered a major independent factor responsible for increased perioperative morbidity and mortality: in particular, in patients with preoperative compromised clinical conditions. in fact, acute pain may compromise the patient's mobilization and the secretion's clearance with secondary possible bronchial obstruction and parenchymal lung infection. today, the treatment of postoperative pain after lung resection is based on association of the pharmacological therapy, including systemic use of opioids and non-steroid drugs, epidural analgesia, intercostal nerve block and cryoanalgesia with the minimally invasive surgery, like use of mini-thoracotomy, a thoracoscopic approach or intercostal nerve protection with the use of muscle sparing. in the literature, reduced tissue damage consequent to the use of limited surgical approaches is reported to be significantly effective in decreasing early postoperative pain. thus, the use of a minimally invasive surgery for lung resections has proved to produce more tolerable pain and allow quicker functional recovery and lower postoperative complications. the aim of this prospective randomized study was to evaluate the equivalency of a smaller incision (4 cm) when compared to a longer length (8 cm) of incision performing uniportal vats lobectomy in terms of postoperative pain results. primarily, to evaluate the differences of operative time between the groups. secondly, to investigate the differences of pain scores between the two groups and the impact of pain reduction on functional results.


Eligibility criteria:
inclusion criteria: * be aged ≥ 18 years (of either gender) * have provided written informed consent prior to participation in the study * undergoing to major lung surgery with an uniportal videothoracocopic access (uvats). exclusion criteria: * rethoracotomy * presence of pleural adhesions * neuropathy * be a participant in another interventional clinical trial or have received another investigational device or device within the last 30 days (donation of excised tissue \[lung or parts of lymph nodes\] for biological research may occur in the same patients)
survey of current interventional and diagnostic imaging residents after participation in endovascular simulator training

Conditions: Malignant Vascular Neoplasm

Summary: this study looks at the comfort of interventional and diagnostic imaging residents in performing simulated endovascular procedures after completing training on the mentice endovascular simulator device. implementation of a training curriculum with radiology residents interested in interventional radiology will help facilitate hands-on training in a low-risk environment and allow for safer future patient encounters.

primary objective: i. to measure trainee comfort performing simulated endovascular procedures after completing training on the mentice endovascular simulator device. outline: participants complete a survey over 10 minutes before and after completing training and using the mentice endovascular simulator device.

Eligibility criteria:
inclusion criteria: - current interventional and diagnostic radiology residents participating in the training curriculum on the mentice endovascular simulator will be eligible to participate in the survey